ABCL
AbCellera Biologics, Inc.
NASDAQ · Healthcare · Biotechnology · CA
$12.63
−0.79%Next report
Analyst consensus
- Next report date
- Nov 5, 2026
- EPS estimate
- -$0.18
- Revenue estimate
- $5.3M
Latest reported
- Last report date
- Aug 5, 2026
- EPS actual
- -$0.18
- EPS estimate
- -$0.16
- Revenue actual
- $4.0M
- Revenue estimate
- $7.8M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 7
- EPS misses (12Q)
- 5
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +24.6%
- Revenue beats (12Q)
- 6
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $16
- PT range
- $9.00 – $30
- Analysts
- 4
4 Buy0 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 5, 2026 | -$0.16 | -$0.18 | Miss -9.76% | $4.0M |
| May 11, 2026 | -$0.22 | -$0.14 | Beat 36.36% | $8.3M |
| Feb 24, 2026 | -$0.18 | -$0.03 | Beat 83.36% | $44.9M |
| Nov 6, 2025 | -$0.17 | -$0.19 | Miss -11.76% | $9.0M |
| Aug 7, 2025 | -$0.17 | -$0.12 | Beat 29.41% | $17.1M |
| May 8, 2025 | -$0.17 | -$0.15 | Beat 11.76% | $4.2M |
| Feb 27, 2025 | -$0.15 | -$0.11 | Beat 26.67% | $5.0M |
| Feb 20, 2024 | -$0.14 | -$0.17 | Miss -21.43% | $9.2M |
| Nov 2, 2023 | -$0.14 | -$0.10 | Beat 28.57% | $6.6M |
| Aug 3, 2023 | -$0.13 | -$0.11 | Beat 15.38% | $10.1M |
| May 4, 2023 | -$0.12 | -$0.14 | Miss -16.67% | $12.2M |
| Feb 21, 2023 | -$0.01 | -$0.10 | Miss -1804.76% | $485.4M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 5, 2026